CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — Q4 2015 Earnings Presentation
23 slides from CytoSorbents's earnings presentation, Mar 9, 2016
Slide 1: CytoSorbents Corporation Q4 and Full Year 2015 Earnings Conference Call
CytoSorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q4 and Full Year 2015 Earnings Conference Call March 9, 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents is A Leader in Critical Care Immunotherapy
CytoSorbents is A Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification 3
Slide 4: CytoSorb Removes the Fuel to the Fire
CytoSorb® Removes the Fuel to the Fire • CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery • Approved in the European Union as the only specifically approved extracorporeal cytokine filter • Clinically proven to remove key cytokines in the blood of critically-ill pa
Slide 5: Goal: To Prevent or Treat Organ Failure
Goal: To Prevent or Treat Organ Failure Improve Decrease Patient Costs Of Outcome ICU and and Patient Survival Care Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine 5
Slide 6: Operating and Financial Highlights
Operating and Financial Highlights 6
Slide 7: 2015 Comparative Revenue Results
2015 Comparative Revenue Results Year Ended Year Ended Dec 31, 2015 Dec 31, 2014 % Incr. Product revenue $ 4,043,819 $ 3,135,387 29% Grant and other income 747,797 987,438 (24)% Total revenue $ 4,791,616 $ 4,122,825 16% • CytoSorb® product sales were $4.0M in 2015, a 29% increase over product sales
Slide 8: Quarterly Euro-Adjusted Product Sales
Quarterly “Euro-Adjusted” Product Sales $2,000,000 CytoSorb® "Euro Adjusted" Product Sales $1,800,000 $1,723,464 $1,600,000 $1,400,000 1,221,694 $1,200,000 $1,031,761 $1,000,000 $920,041 $871,150 $816,109 $800,000 $663,233 $569,243 $600,000 $400,000 $314,159 $176,098 $203,561 $200,000 $87,960 $127,9
Slide 9: Working Capital and Cap Table
Working Capital and Cap Table Working Capital as of 12/31/15 12/31/14 12/31/13 12/31/12 Current Assets: Cash and short-term investments $ 7,508 $ 5,550 $ 2,183 $ 1,729 Grants and accounts receivable, net 649 819 453 51 Inventories 1,191 538 245 682 Prepaid expenses and other current assets 512 700 6
Slide 10: Operating Highlights
Operating Highlights med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 11: 3rd International CytoSorb Users Meeting
3rd International CytoSorb Users Meeting • CytoSorbents will host its 3rd International CytoSorb Users Meeting in Brussels, Belgium on March 14, 2016 • Currently, more than 100 people are registered to attend the meeting from a total of 22 countries • Agenda includes 12 clinical and pre-clinical pre
Slide 12: 36th ISICEM Conference
36th ISICEM Conference • The International Symposium of Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium from March 15-18, 2016 is one of the largest, most prominent critical care conferences in the world • CytoSorbents is a Gold Sponsor and will exhibit and host a research sympos
Slide 13: Fresenius Medical Care and ISICEM
Fresenius Medical Care and ISICEM • Fresenius will initiate the marketing push behind CytoSorb® at the ISICEM Conference in Brussels, Belgium next week ahead of a forthcoming launch • CytoSorb® will be featured in the Fresenius exhibition booth on the multiFiltrate Acute Therapy System • Fresenius w
Slide 14: Biocon and Cardiac Surgery Partners
Biocon and Cardiac Surgery Partners • Biocon and CytoSorbents recently completed a four city, week-long trip in India and Sri Lanka with Prof. Dr. Zsolt Molnar, Chairman of SepsEast, the Central and Eastern European Sepsis Forum and experienced user of CytoSorb for critical illnesses • Introduced Cy
Slide 15: REFRESH I Trial Update
REFRESH I Trial Update REduction in FREe Hemoglobin • 40-patient, eight-center study evaluating the safety and efficacy of intra-operative use of CytoSorb® in a heart-lung machine during complex cardiac surgery in elective, non-emergent cardiac surgery > 3 hours • Aortic reconstruction, CABG redos,
Slide 16: REFRESH I Trial Update
REFRESH I Trial Update REduction in FREe Hemoglobin Trial • Working with major cardiac surgery centers • Baylor College of Medicine • Baystate Medical Center • Columbia University • Cooper University Hospital • University of Kentucky • University of Maryland • University of Pennsylvania • University
Slide 17: International CytoSorb Registry Update
International CytoSorb® Registry Update • The CytoSorb registry is intended to collect treatment data from all over the world • It is funded by CytoSorbents, but is managed independently by the Center of Clinical Studies at University of Jena led by Prof. Dr. med. Frank Brunkhorst • The analysis of
Slide 18: Sepsis Definition Update
Sepsis Definition Update The Third International Consensus Definitions Task Force just published their new guidelines for the definition of sepsis in JAMA* Sepsis was defined as: “The life-threatening organ dysfunction caused by a dysregulated host response to infection” •This aligns very well with
Slide 19: Select Case Reports
Select Case Reports med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 20: Refractory Septic Shock
Refractory Septic Shock At the 26th Symposium for Intensive Medicine + Critical Care in Bremen, Germany, Dr. Sigrun Friesecke, Senior Intensivist in the Greifswald University Hospital MICU reported on a prospective, single arm study in 22 patients with refractory late-stage septic shock • Patients h
Slide 21: Severe Burn Injury
Severe Burn Injury • 51 year old man was admitted and acutely treated for severe burn injury (60% BSA) and inhalation trauma due to an explosion accident • On Day 2, the patient developed acute kidney failure requiring dialysis • He subsequently developed shock requiring high doses of vasopressors (
Slide 22: CytoSorb SIRS and Sepsis: Regain Control!
CytoSorb® SIRS and Sepsis: Regain Control! 22
Slide 23: Q&A Session
Q&A Session CytoSorbents Corporation NASDAQ: CTSO Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 [email protected] A Leader in Critical Care Immunotherapy Company 23